biostudies-literatureUnknown143(1)Gold MR<h4>Background</h4>The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, had less left ventricular dysfunction, and received more inappropriate shocks (IAS) than in typical transvenous ICD trials. The UNTOUCHED trial (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction) was designed to evaluate the IAS rate in a more typical, contemporary ICD patient population implanted with the S-ICD using standardized programming and enhanced discrimination algorithms.<h4>Methods</h4>Primary prevention patients with left ventricular ejection fraction ≤35% and no pacing indications were included. Generation 2 or 3 S-ICD devCirculation7-17https://www.ebi.ac.uk/biostudies/studies/S-EPMC7752215biostudies-literaturePrimary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.PMC7752215Saba SGehi AKnops REHassankhani ADoshi RBarr CSDinerman JGreenstein RCiuffo AStein KMUNTOUCHED Investigators*Viani SCassidy CWright DRusso AMSmelley MRowe SGold MRHohnloser SMark GPasquie JLSagi VEl-Chami MFBusch MFedor MMolin FCastellano Perez NSteffel JPhilliopon FPhelan TBrock JKim BClancy JKuk RIrles DTrojan MKim ELee MHenderson RRhodes TLeclercq CBhakta DVarkey SChauvin MGranrud GKnight BRajendra ABoersma LVAAl-Ameri HMerchant FMoccetti TPerez-Gil FDeharo JCLee SCChinitz JNsah EUpadhyay GKaranam SCrossen KWiggins SKlein CTabbal GWeiner SBongiorni MGLenz CHuang DTheuns DRoberts PKoide NGosau NAlbirini ASegerson NPanday MBadenco NKazemian PBindra SCarter NTimmers LTsai SAasbo JDCalvo NKalahasty GEckardt LZadeh ABertaux GKhairallah FLewis NTendler DMarzak HLewis RMcDonnell KGottlieb CMorani GBoveda SFreedman RPtaszynski PMckenzie JMobarek SStoltz TBlangy HMarquie CHamdan FLambiase PDScott LShakir AHanon SGoethals PSchutzman JBrisben AJZitron EAlimohammad RDe Filippo PMorin DWeiss RSchoenhard JDevecchi FNg GArias MSarter BShaik NBurke MCSturdivant JLfalsePrimary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial.<h4>Background</h4>The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prevention. However, patients in previous S-ICD studies had fewer comorbidities, had less left ventricular dysfunction, and received more inappropriate shocks (IAS) than in typical transvenous ICD trials. The UNTOUCHED trial (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction) was designed to evaluate the IAS rate in a more typical, contemporary ICD patient population implanted with the S-ICD using standardized programming and enhanced discrimination algorithms.<h4>Methods</h4>Primary prevention patients with left ventricular ejection fraction ≤35% and no pacing indications were included. Generation 2 or 3 S-ICD dev2021-01-01T00:00:00Z2021 Jan2026-04-28T22:53:26.968Z2021-02-20T15:06:54ZS-EPMC77522153307361410.1161/CIRCULATIONAHA.120.048728